{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:41:11Z","timestamp":1791650471733,"version":"4.3.4"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017412","name":"Becton Dickinson and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ygyno.2026.02.016","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T19:57:08Z","timestamp":1772654228000},"page":"40-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["HPV genotype prevalence in low- and high-vaccine coverage, USA populations: Data from real-world cervical cancer screening using the Onclarity HPV assay"],"prefix":"10.1016","volume":"207","author":[{"given":"Didier","family":"Morel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Parvu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"Stephenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Bull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alanna","family":"Woodward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Vaughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2026.02.016_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CMR.16.1.1-17.2003","article-title":"Human papillomavirus and cervical cancer","volume":"16","author":"Burd","year":"2003","journal-title":"Clin. Microbiol. Rev."},{"issue":"2","key":"10.1016\/j.ygyno.2026.02.016_bb0010","doi-asserted-by":"crossref","first-page":"18","DOI":"10.32481\/djph.2019.05.005","article-title":"Vaccination is the most effective strategy for HPV prevention","volume":"5","author":"Savoy","year":"2019","journal-title":"Dela J. Public Health"},{"issue":"11","key":"10.1016\/j.ygyno.2026.02.016_bb0015","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"de Sanjose","year":"2010","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2026.02.016_bb0020","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/path.4424","article-title":"Are 20 human papillomavirus types causing cervical cancer?","volume":"234","author":"Arbyn","year":"2014","journal-title":"J. Pathol."},{"issue":"10","key":"10.1016\/j.ygyno.2026.02.016_bb0025","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/jnci\/djaa011","article-title":"Evaluation of durability of a single dose of the bivalent HPV vaccine: the CVT trial","volume":"112","author":"Kreimer","year":"2020","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2026.02.016_bb0030","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-050669","article-title":"Human papillomavirus vaccine efficacy against invasive, HPV-positive cancers: population-based follow-up of a cluster-randomised trial","volume":"11","author":"Lehtinen","year":"2021","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.ygyno.2026.02.016_bb0035","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1080\/14760584.2023.2287135","article-title":"Comparative efficacy of human papillomavirus vaccines: systematic review and network meta-analysis","volume":"22","author":"Lin","year":"2023","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.ygyno.2026.02.016_bb0040","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2239085","article-title":"Human papillomavirus vaccine effectiveness by age at vaccination: a systematic review","volume":"19","author":"Ellingson","year":"2023","journal-title":"Hum. Vaccin. Immunother."},{"issue":"12","key":"10.1016\/j.ygyno.2026.02.016_bb0045","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2022.4716","article-title":"Human papillomavirus vaccine administration trends among commercially insured US adults aged 27-45 years before and after advisory committee on immunization practices recommendation change, 2007-2020","volume":"3","author":"Suk","year":"2022","journal-title":"JAMA Health Forum"},{"issue":"26","key":"10.1016\/j.ygyno.2026.02.016_bb0050","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.1016\/j.vaccine.2018.05.019","article-title":"Decline of HPV infections in Scandinavian cervical screening populations after introduction of HPV vaccination programs","volume":"36","author":"Dillner","year":"2018","journal-title":"Vaccine"},{"issue":"32","key":"10.1016\/j.ygyno.2026.02.016_bb0055","doi-asserted-by":"crossref","first-page":"3922","DOI":"10.1016\/j.vaccine.2017.06.028","article-title":"Seropositivity to non-vaccine incorporated genotypes induced by the bivalent and quadrivalent HPV vaccines: a systematic review and meta-analysis","volume":"35","author":"Bissett","year":"2017","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.ygyno.2026.02.016_bb0060","article-title":"Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6\/16\/18\/31\/33\/45\/52\/58 induced by bivalent and quadrivalent HPV vaccines","volume":"5","author":"Mariz","year":"2020","journal-title":"NPJ Vacc."},{"issue":"4","key":"10.1016\/j.ygyno.2026.02.016_bb0065","article-title":"Selective persistence of HPV cross-neutralising antibodies following reduced-dose HPV vaccine schedules","volume":"7","author":"Toh","year":"2019","journal-title":"Vaccines (Basel)"},{"issue":"10","key":"10.1016\/j.ygyno.2026.02.016_bb0070","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1093\/jnci\/djaa010","article-title":"Durability of cross-protection by different schedules of the bivalent HPV vaccine: the CVT trial","volume":"112","author":"Tsang","year":"2020","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.ygyno.2026.02.016_bb0075","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(11)70287-X","article-title":"Cross-protective efficacy of HPV-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Wheeler","year":"2012","journal-title":"Lancet Oncol."},{"issue":"2 Suppl 1","key":"10.1016\/j.ygyno.2026.02.016_bb0080","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.ygyno.2007.08.059","article-title":"Human papillomavirus vaccines and the potential for cross-protection between related HPV types","volume":"107","author":"Ault","year":"2007","journal-title":"Gynecol. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2026.02.016_bb0085","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.jogc.2018.05.024","article-title":"A review of the impact and effectiveness of the quadrivalent human papillomavirus vaccine: 10 years of clinical experience in Canada","volume":"40","author":"Steben","year":"2018","journal-title":"J. Obstet. Gynaecol. Can."},{"issue":"8","key":"10.1016\/j.ygyno.2026.02.016_bb0090","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/infdis\/jiad080","article-title":"Effects of 2 and 3 vaccinations with the bivalent human papillomavirus (HPV) vaccine on the prevalence and load of HPV in clearing and persistent infections in young women","volume":"228","author":"van Eer","year":"2023","journal-title":"J. Infect. Dis."},{"issue":"9","key":"10.1016\/j.ygyno.2026.02.016_bb0095","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/jnci\/djac107","article-title":"Performance of cervical screening a decade following HPV vaccination: the Costa Rica vaccine trial","volume":"114","author":"Hu","year":"2022","journal-title":"J. Natl. Cancer Inst."},{"issue":"16","key":"10.1016\/j.ygyno.2026.02.016_bb0100","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/j.vaccine.2020.11.076","article-title":"Systematic literature review of cross-protective effect of HPV vaccines based on data from randomized clinical trials and real-world evidence","volume":"39","author":"Brown","year":"2021","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.ygyno.2026.02.016_bb0105","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.3201\/eid2210.160675","article-title":"Population-level effects of human papillomavirus vaccination programs on infections with nonvaccine genotypes","volume":"22","author":"Mesher","year":"2016","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.ygyno.2026.02.016_bb0110","article-title":"An update on human papilloma virus vaccines: history, types, protection, and efficacy","volume":"12","author":"Yousefi","year":"2021","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.ygyno.2026.02.016_bb0115","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/CEJ.0000000000000565","article-title":"Trends in prevalence in human papillomavirus types and their association with cervical dysplasia: an analysis on 15 138 women over 20 years","volume":"29","author":"Bogani","year":"2020","journal-title":"Eur. J. Cancer Prev."},{"issue":"7","key":"10.1016\/j.ygyno.2026.02.016_bb0120","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw300","article-title":"Evaluation of type replacement following HPV16\/18 vaccination: pooled analysis of two randomized trials","volume":"109","author":"Tota","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2026.02.016_bb0125","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-068582","article-title":"National experience in the first two years of primary human papillomavirus (HPV) cervical screening in an HPV vaccinated population in Australia: observational study","volume":"376","author":"Smith","year":"2022","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.ygyno.2026.02.016_bb0130","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/j.chom.2023.10.001","article-title":"Ecological diversity profiles of non-vaccine-targeted HPVs after gender-based community vaccination efforts","volume":"31","author":"Pimenoff","year":"2023","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ygyno.2026.02.016_bb0135","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djaf055","article-title":"HPV vaccine impact: genotype-specific changes in cervical pre-cancer share similarities with changes in cervical screening cytology","volume":"117","author":"Adcock","year":"2025","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2026.02.016_bb0140","doi-asserted-by":"crossref","unstructured":"C.M. Wheeler, et al., Human papillomavirus genotype-specific prevalence and infection risks: a 10-year population-based study from the United States, J. Natl. Cancer Inst. (2025);117(5):924-933. doi:10.1093\/jnci\/djae327","DOI":"10.1093\/jnci\/djae327"},{"issue":"5 Suppl 1","key":"10.1016\/j.ygyno.2026.02.016_bb0145","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/LGT.0b013e318287d329","article-title":"2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors","volume":"17","author":"Massad","year":"2013","journal-title":"J. Low. Genit. Tract. Dis."},{"issue":"3","key":"10.1016\/j.ygyno.2026.02.016_bb0150","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ygyno.2018.04.007","article-title":"The Onclarity human papillomavirus trial: design, methods, and baseline results","volume":"149","author":"Stoler","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.02.016_bb0155","doi-asserted-by":"crossref","first-page":"243e1","DOI":"10.1016\/j.ajog.2023.09.100","article-title":"Comparing the performance of 2 human papillomavirus assays for a new use indication: a real-world evidence-based evaluation in the United States","volume":"230","author":"Wheeler","year":"2024","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2026.02.016_bb0160","author":"Centers for Disease Control and Prevention"},{"key":"10.1016\/j.ygyno.2026.02.016_bb0165","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.pvr.2018.10.010","article-title":"Changes in human papillomavirus genotypes associated with cervical intraepithelial neoplasia grade 2 lesions in a cohort of young women (2013-2016)","volume":"6","author":"Innes","year":"2018","journal-title":"Papillomavirus Res."},{"issue":"12","key":"10.1016\/j.ygyno.2026.02.016_bb0170","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(17)30468-1","article-title":"Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study","volume":"17","author":"Kavanagh","year":"2017","journal-title":"Lancet Infect. Dis."},{"issue":"6","key":"10.1016\/j.ygyno.2026.02.016_bb0175","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/infdis\/jiy249","article-title":"The impact of the national HPV vaccination program in England using the bivalent HPV vaccine: surveillance of type-specific HPV in young females, 2010-2016","volume":"218","author":"Mesher","year":"2018","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.ygyno.2026.02.016_bb0180","article-title":"Differential long-term bivalent HPV vaccine cross-protection by variants in the Costa Rica HPV vaccine trial","volume":"9","author":"Shing","year":"2024","journal-title":"NPJ Vacc."},{"key":"10.1016\/j.ygyno.2026.02.016_bb0185","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jviromet.2014.12.007","article-title":"In vitro assessment of the effect of vaccine-targeted human papillomavirus (HPV) depletion on detection of non-vaccine HPV types: implications for post-vaccine surveillance studies","volume":"214","author":"Cornall","year":"2015","journal-title":"J. Virol. Methods"},{"issue":"9","key":"10.1016\/j.ygyno.2026.02.016_bb0190","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1128\/JCM.00539-06","article-title":"Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR","volume":"44","author":"van Doorn","year":"2006","journal-title":"J. Clin. Microbiol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.02.016_bb0195","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/infdis\/jiaa032","article-title":"Human papillomavirus genotype replacement: still too early to tell?","volume":"224","author":"Man","year":"2021","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.ygyno.2026.02.016_bb0200","doi-asserted-by":"crossref","DOI":"10.1080\/14767058.2023.2183769","article-title":"Association between loop electrosurgical excision procedure and adverse pregnancy outcomes: a meta-analysis","volume":"36","author":"Liu","year":"2023","journal-title":"J. Matern. Fetal Neonatal Med."},{"issue":"4","key":"10.1016\/j.ygyno.2026.02.016_bb0205","article-title":"The burden of cervical conization in privately insured young and mid-adult women in the United States","volume":"11","author":"Saxena","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"10451","key":"10.1016\/j.ygyno.2026.02.016_bb0210","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0140-6736(24)01097-3","article-title":"Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature","volume":"404","author":"Wei","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ygyno.2026.02.016_bb0215","first-page":"14","article-title":"Trends in cervical cancer screening modality in the active component U.S. military, 2013-2023","volume":"32","author":"Ginn","year":"2025","journal-title":"MSMR"},{"issue":"2","key":"10.1016\/j.ygyno.2026.02.016_bb0220","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1128\/CVI.00457-14","volume":"22","author":"Struyf","year":"2015","journal-title":"Clin. Vaccine Immunol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.02.016_bb0225","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/LGT.0000000000000865","article-title":"Applying results of extended genotyping to management of positive cervicovaginal human papillomavirus test results: enduring guidelines","volume":"29","author":"Massad","year":"2025","journal-title":"J. Low. Genit. Tract. Dis."},{"issue":"1","key":"10.1016\/j.ygyno.2026.02.016_bb0230","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1146\/annurev-virology-110615-042323","article-title":"Symbiosis: viruses as intimate partners","volume":"4","author":"Roossinck","year":"2017","journal-title":"Annu. Rev. Virol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826008103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826008103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T14:58:33Z","timestamp":1777474713000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825826008103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":46,"alternative-id":["S0090825826008103"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.02.016","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HPV genotype prevalence in low- and high-vaccine coverage, USA populations: Data from real-world cervical cancer screening using the Onclarity HPV assay","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.02.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}